Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) is now available.
Hangzhou Tigermed Consulting has proposed a final ordinary cash dividend of RMB 1.26 per 10 shares for the financial year ended 31 December 2025, with payment scheduled for 31 July 2026. Key details including shareholder approval date, currency for Hong Kong shareholders, exchange rate, ex-dividend date, record date and applicable withholding tax are yet to be announced, leaving investors awaiting clarity on the exact distribution mechanics and net payout.
The dividend announcement underscores the company’s intention to return cash to shareholders following its 2025 performance, signaling confidence in its financial position and cash generation. However, the number of unresolved parameters, particularly around tax treatment and currency arrangements, means stakeholders will need to monitor subsequent disclosures to fully assess the dividend’s impact on their actual returns and the stock’s income appeal.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$61.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a China-based clinical research and pharmaceutical services provider listed in Hong Kong, operating in the biopharmaceutical contract research and consulting industry. The company focuses on supporting drug development and related medical research for clients, positioning itself within the broader healthcare and life sciences services sector.
YTD Price Performance: -2.63%
Average Trading Volume: 2,034,252
Technical Sentiment Signal: Sell
Current Market Cap: HK$46.16B
See more data about 3347 stock on TipRanks’ Stock Analysis page.